Pear Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Pear Therapeutics's estimated annual revenue is currently $59.2M per year.
- Pear Therapeutics received $64.0M in venture funding in January 2019.
- Pear Therapeutics's estimated revenue per employee is $177,800
- Pear Therapeutics's total funding is $409M.
- Pear Therapeutics has 333 Employees.
- Pear Therapeutics grew their employee count by 29% last year.
Pear Therapeutics Competitors & Alternatives
|Competitor Name||Revenue||Number of Employees||Employee Growth||Total Funding||Valuation|
What Is Pear Therapeutics?
At Pear, our mission is clear: we are pioneers in Prescription Digital Therapeutics, or PDTs. Our cross-functional team operates at the intersection of biotechnology and software technology. Pear discovers, develops, and delivers clinically-validated software-based therapeutics to provide better outcomes for patients, smarter engagement and tracking tools for clinicians, and cost-effective solutions for payers. Every day, we push the boundaries of technology to transform medicine. Pear has a pipeline of products and product candidates across therapeutic areas, including mental health disorders, severe insomnia and multiple sclerosis. Our lead product, reSET®, treats Substance Use Disorder, and was the first PDT to receive marketing authorization from the FDA to treat disease. Pear's second product candidate, reSET-O for the treatment of Opioid Use Disorder, is currently under review by the FDA with Breakthrough Designation. For more information, visit us at www.peartherapeutics.com.keywords:Biotechnology,Gaming,Healthcare,Human Resources Hr,Information Security,Medical Diagnostics,Mobile,Pharmaceuticals,Security
Number of Employees
Employee Growth %
Pear Therapeutics News
Pear to host panel discussion with leaders who are paving the way to provide patients access to prescription digital therapeutics for the...
Boston-based Pear's program offers patients seeking treatment for substance use disorder (SUD) or opioid use disorder (OUD) access to a...
In its first year-end financial report after going public via reverse merger last December, Pear Therapeutics inched past nearly all of its predictions for...
What You Should Know: – Pear Therapeutics, the leader in developing and commercializing prescription digital therapeutics to treat serious disease, and Thimble Point Acquisition Corp (Nasdaq: THMA), a special purpose acquisition company (SPAC) whose management team is associated with the Pritzk ...
|Company Name||Revenue||Number of Employees||Employee Growth||Total Funding|
Pear Therapeutics Funding